10-K: Ionis Pharmaceuticals Reports Strong 2025 Revenue Growth

Ionis Pharmaceuticals, a leader in RNA-targeted medicines, reported significant revenue growth in 2025 driven by new product launches and a robust pipeline, despite a net loss.

Summary

• Total revenue for 2025 was $943.7 million, a substantial increase from $705.1 million in 2024.
• Commercial revenue surged by 49% in 2025, primarily fueled by the independent launches of TRYNGOLZA ($107.5 million in sales) and DAWNZERA ($7.8 million in sales).
• Royalty revenue reached $285.5 million in 2025, up from $257.3 million in 2024, largely due to increased WAINUA royalties of $49.1 million.
• Research and development (R&D) revenue contributed $507.9 million in 2025, including a $280 million upfront payment from Ono for sapablursen.
• The net loss for 2025 improved to $381.4 million, compared to a $453.9 million net loss in 2024.
• The company maintained a strong liquidity position, ending 2025 with $2.7 billion in cash, cash equivalents, and short-term investments.
• Two independent product launches are anticipated in 2026: olezarsen for severe hypertriglyceridemia (sHTG) with a PDUFA action date of June 30, 2026, and zilganersen for Alexander disease (AxD) following an NDA submission in January 2026.
• Obudanersen for Angelman syndrome advanced into a Phase 3 study in the second quarter of 2025.
• Positive topline Phase 3 results for partnered bepirovirsen in chronic hepatitis B were announced in January 2026.
• Novartis terminated a collaboration for a new Lp(a)-driven cardiovascular disease medicine in 2025.
• The company repurchased $200 million of its 0% Notes due 2026 using proceeds from a new $770 million offering of 0% Notes due 2030.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, highlighting significant revenue growth driven by new product launches and a robust pipeline, alongside a reduced net loss. The progress in late-stage development and strategic partnerships indicates positive momentum, despite ongoing operational costs and competitive pressures.

Positives

• Total revenue increased by 33.8% from $705.1 million in 2024 to $943.7 million in 2025, demonstrating strong top-line growth.
• Commercial revenue grew by 49% year-over-year, driven by successful independent launches of TRYNGOLZA ($107.5 million sales) and DAWNZERA ($7.8 million sales) in the U.S.
• Net loss decreased from $453.9 million in 2024 to $381.4 million in 2025, indicating improved financial performance.
• Ended 2025 with a robust cash, cash equivalents, and short-term investment balance of $2.7 billion, providing ample liquidity for future investments.
• Received a significant $280 million upfront payment from Ono for the global license of sapablursen, highlighting the value of the pipeline.
• FDA granted Priority Review for olezarsen for severe hypertriglyceridemia (sHTG), with a PDUFA action date of June 30, 2026, signaling potential near-term market expansion.
• Submitted New Drug Application (NDA) for zilganersen for Alexander disease (AxD) in January 2026, with a planned launch in the second half of 2026.
• Advanced obudanersen into a Phase 3 study for Angelman syndrome in Q2 2025, expanding the wholly-owned late-stage pipeline.
• Announced positive topline results from pivotal Phase 3 studies for partnered bepirovirsen in chronic hepatitis B in January 2026, indicating strong clinical progress.
• WAINUA royalties significantly increased from $20.2 million in 2024 to $49.1 million in 2025, reflecting growing market penetration for this partnered medicine.
• Maintained effective internal control over financial reporting as of December 31, 2025, as attested by management and independent auditors.

Negatives

• Continued to incur a net loss of $381.4 million in 2025, extending the period of unprofitability since inception.
• SPINRAZA royalties slightly decreased from $216.1 million in 2024 to $212.3 million in 2025, with Biogen citing increased competition and lower pricing as factors impacting sales.
• Novartis terminated a collaboration and license agreement for a new Lp(a)-driven cardiovascular disease medicine in 2025, indicating a setback in that specific pipeline program.
• Roche discontinued development of sefaxersen for geographic atrophy (GA) in July 2024 due to insufficient efficacy, despite a favorable safety profile.
• Total operating expenses increased to $1,325.4 million in 2025 from $1,180.2 million in 2024, primarily due to investments in commercialization efforts.
• Investment income decreased from $107.0 million in 2024 to $97.8 million in 2025, attributed to a decrease in interest rates.
• Recognized an induced conversion expense of $16.3 million in 2025 related to the repurchase of 0% Notes due 2026, impacting other expense.
• Fourth-quarter 2025 revenue was lower than the same period in 2024, primarily due to significant non-recurring partner payments in Q4 2024.

Risks

• Limited experience in commercializing medicines independently, requiring significant financial and management resources to build and maintain infrastructure, which may not be effective.
• Market acceptance of medicines is uncertain, depending on efficacy, safety, cost-effectiveness, patient convenience, and reimbursement policies, which could limit revenue generation.
• Inadequate coverage and payment rates from government and third-party payers, or increased costs due to healthcare reform measures (e.g., Inflation Reduction Act of 2022), could limit revenue.
• Intense competition from major pharmaceutical and biopharmaceutical companies, including those with greater resources and experience, could make products obsolete or non-competitive.
• Regulatory limitations following approval, such as restrictions on product labels, required post-marketing studies, or withdrawal of marketing authorization due could impact commercial success.
• Dependence on collaborations with partners (e.g., Biogen, AstraZeneca, GSK, Novartis, Otsuka, Roche) for development, funding, and commercialization, with risks of partners failing to fulfill obligations or terminating agreements.
• Inability to expand manufacturing capabilities or manufacture medicines at costs that allow for competitive pricing, potentially limiting commercial success.
• High inherent risks in drug discovery and development; clinical trials may fail or be delayed, leading to abandonment of programs.
• Reliance on third parties to conduct clinical studies, with risks of delays, non-compliance, or termination of relationships.
• Potential loss of Orphan Drug exclusivity if conditions are not met or competitors gain approval for substantially similar medicines.
• Failure to obtain timely funding could lead to curtailment or abandonment of research, drug discovery, or development programs, or commercial operations.
• History of incurring losses and the risk of failing to consistently achieve profitability in the future.
• Inability to protect patent rights or other proprietary rights, potentially allowing competitors to compete more effectively.
• Intellectual property litigation (e.g., lawsuit against Arrowhead Pharmaceuticals) could be expensive, distracting, and negatively impact the business.
• Exposure to potential product liability claims inherent in testing, manufacturing, marketing, and sale of therapeutic products, with insurance coverage potentially being inadequate.
• Loss of key personnel or inability to attract and retain highly skilled personnel could hinder business operations and success.
• Adverse effects on business from health epidemics, climate change, extreme weather events, fires, earthquakes, war, civil or political unrest, terrorism, or disruptions of the U.S. government.
• Data protection risks due to dependence on information technology systems and infrastructure, exposing the company to cybersecurity threats, data breaches, and non-compliance with privacy laws (e.g., GDPR, CCPA).
• Challenges with properly managing the increasing use of social media platforms and artificial intelligence could adversely affect the business, reputation, or financial results.
• Stock price volatility due to various factors, including fluctuations in operating results, financing transactions, clinical study results, and market perception.
• Negative conditions in the global credit markets and financial services industries could make necessary debt or equity financing more difficult or costly.
• Risks associated with international operations, including unfavorable regulatory, pricing, political, tax, and labor conditions, and compliance with anti-corruption laws like the FCPA.
• Provisions in the certificate of incorporation, bylaws, convertible notes documents, call spread hedge transaction documents, and Delaware law may prevent stockholders from receiving a premium for their shares in an acquisition.
• Future sales of common stock in the public market could adversely affect the trading price of securities due to potential dilution from convertible notes and warrants.
• Operations are subject to extensive legal and regulatory requirements in the healthcare industry, with potential for significant civil, criminal, and administrative penalties for non-compliance.
• Risks related to the use of biological materials, hazardous materials, chemicals, and radioactive compounds, including contamination and liabilities under environmental and safety laws.
• Increased costs and risk of noncompliance due to changing regulations for corporate governance and public disclosure (e.g., Sarbanes-Oxley Act, Dodd-Frank Act).
• Ability to use net operating loss carryovers and certain other tax attributes may be limited by ownership changes (Sections 382 and 383 of the Code) or state-level suspensions (e.g., California Senate Bill 167).
• Potential for additional tax liabilities due to changes in tax laws, regulations, treaties, or outcomes of tax audits (e.g., OECD BEPS project, IRS examination for 2023).

Future Outlook

Ionis Pharmaceuticals expects to independently launch two new medicines in 2026, olezarsen for severe hypertriglyceridemia (sHTG) and zilganersen for Alexander disease (AxD), assuming regulatory approvals. The company anticipates increasing product and royalty revenue over the next two years from current and planned launches. Medical affairs and commercialization expenses are projected to rise as WAINUA advances, while development expenses are expected to stabilize as late-stage studies conclude and resources shift to earlier-stage programs. The company plans to expand manufacturing infrastructure through CMOs and additional suppliers to meet future demand and will publish its 2025 Corporate Responsibility Report in April 2026.

Management Comments

• "For three decades, we have invented medicines that bring better futures to people with serious diseases."
• "In the last year, we delivered on our strategy to create accelerating value for all our stakeholders."
• "With two independent commercial launches now underway, we transitioned into a fully integrated commercial-stage biotechnology company."
• "Our key recent achievements, combined with our independent and partnered product launches anticipated over the next two years, position us well to help millions of patients with serious diseases and deliver increasing product and royalty revenue."
• "We believe that the future will be defined by outstanding people and we are committed to recruiting, developing, motivating, and rewarding them."

Industry Context

StockSavvy.ai notes that Ionis Pharmaceuticals is solidifying its position as a fully integrated commercial-stage biotechnology company, a significant transition from its historical reliance on partnerships. The company's focus on RNA-targeted medicines aligns with a growing trend in precision medicine, addressing the root causes of diseases. Its robust late-stage pipeline and recent positive data readouts suggest continued innovation in neurology, cardiometabolic, and rare disease areas, which are high-growth segments within the biopharmaceutical industry. The increasing competition in areas like SMA (SPINRAZA) and ATTRv-PN (WAINUA/TEGSEDI) highlights the dynamic nature of these markets, where novel therapies and improved dosing regimens are key differentiators. The termination of a Novartis collaboration for a new Lp(a)-driven CVD medicine, while a setback, is not uncommon in early-stage drug development and reflects the high-risk nature of the industry.

Comparison to Industry Standards

• **TRYNGOLZA/Olezarsen (FCS/sHTG):** Competes with Arrowhead Pharmaceuticals' Redemplo (Plozasiran) (approved in U.S. for FCS, Phase 3 sHTG), Roche's Pegozafermin (FGF21 analog, Phase 3 sHTG), NorthSea Therapeutics' NST-1024 (CETP Inhibitor, Phase 2 sHTG), and Eli Lilly's Solbinsiran (ANGPTL3 inhibitor; siRNA, Phase 2 sHTG). TRYNGOLZA is the first FDA-approved treatment for FCS to significantly reduce triglycerides and acute pancreatitis events.
• **DAWNZERA (HAE):** Competes with Takeda's Takhzyro (lanadelumab-flyo, monoclonal antibody, approved for HAE patients two years and older) and Cinryze (C1 esterase inhibitor, approved for HAE patients six years and older), BioCryst's Orladeyo (berotralstat, oral plasma kallikrein inhibitor, approved for HAE patients 12 years and older), CSL Behring's Andembry (Garadacimab, anti-factor XIIa monoclonal antibody, approved for HAE patients 12 years and older) and Haegarda (C1 esterase inhibitor, approved for HAE patients 6 years and older). Also faces potential competition from Pharvaris' Deucrictibant (oral B2-receptor antagonist, Phase 3), Intellia's Lonvoguranziclumeran (CRISPR therapeutic, Phase 3), Astria/BioCryst's STAR-0215 (monoclonal antibody, Phase 3), ADARx's ADX-324 (siRNA, Phase 3), and Argo's BW-20805 (siRNA, Phase 2). DAWNZERA is the first and only approved RNA-targeted prophylactic therapy for HAE, offering durable efficacy and a long dosing interval.
• **WAINUA/Eplontersen & TEGSEDI (ATTRv-PN/ATTR-CM):** Competes with Alnylam's Onpattro (Patisiran, RNAi, approved for ATTRv-PN) and Amvuttra (Vutrisiran, RNAi, approved for ATTRv-PN and ATTR-CM), Pfizer's Vyndaqel/Vyndamax (Tafamidis, small molecule, approved for ATTRv-PN in EU/Japan, ATTR-CM in U.S./EU), BridgeBio's Attruby (Acoramidis, small molecule, approved for ATTR-CM), Intellia/Regeneron's NTLA-2001 (CRISPR therapeutic, Phase 3 ATTR-CM/ATTRv-PN), AstraZeneca's Cliramitug (monoclonal IgG1, Phase 3 ATTR-CM), Novo Nordisk's Coramitug (monoclonal antibody, Phase 3 ATTR-CM), and Alnylam's Nucresiran (RNAi, Phase 3 ATTR-CM). WAINUA is the only approved medicine for ATTRv-PN that can be self-administered via an auto-injector.
• **SPINRAZA (SMA):** Competes with Novartis' Zolgensma (Onasemnogene abeparvovec, gene therapy, approved for pediatric SMA patients less than 2 years of age) and Itvisma (Onasemnogene abeparvovec, gene therapy, approved for pediatric and adult SMA patients), and Roche's Evrysdi (Risdiplam, small molecule, approved for pediatric and adult SMA patients). Biogen has noted past revenue decreases for SPINRAZA due to increased competition.
• **QALSODY (SOD1-ALS):** Faces potential competition from Neurimmune (AL-S Pharma) / Lilly's AP-101 (human derived antibody, Phase 2). QALSODY was the first treatment approved to target a genetic cause of ALS.
• **Zilganersen (AxD):** No other medicines in clinical development for AxD are mentioned, indicating a potential first-in-class opportunity.
• **Obudanersen (Angelman syndrome):** Competes with Ultragenyx's Apazunersen (ASO, Phase 3), Oak Hill Bio / Roche's Rugonersen (locked nucleic acid, Phase 3), Roche's Alogabat (small molecule, Phase 2), Neuren's NNZ-2591 (small molecule, Phase 2), and MavriX Bio's MVX-220 (gene therapy, Phase 1/2).
• **Bepirovirsen (HBV):** Competes with Vir Biotech / Alnylam's Elebsiran (RNAi, Phase 2), Arbutus Biopharma's Imdusiran (RNAi, Phase 2), Vir Biotech's Tobevibart (monoclonal antibody, Phase 2), Gilead Sciences' Selgantolimod (Toll-like receptor 8 agonist, Phase 2), Replicor Inc.'s REP 2139-Mg (nucleic acid polymer, Phase 2), Barinthus Bio's VTP-300 (immunotherapy, Phase 2), Brii Biosciences' BRII-179 (immunotherapy, Phase 2), and AusperBio's AHB-137 (ASO, Phase 3 in China).
• **Pelacarsen (Lp(a)-driven CVD):** Competes with Amgen/Arrowhead's Olpasiran (RNAi, Phase 3), Eli Lilly's Lepodisiran (RNAi, Phase 3) and Muvalaplin (small molecule, Phase 3), Argo Biopharmaceutical's DII235 (RNAi, Phase 3 ready), Silence's Zerlasiran (RNAi, Phase 2), and NewAmsterdam Pharma's Obicetrapib (CETP inhibitor, Phase 2).
• **Sefaxersen (IgAN):** Competes with Asahi Kasei (Calliditas)'s Tarpeyo (budesonide, corticosteroid, approved), Travere's Filspari (Sparsentan, endothelin & angiotensin II receptor antagonist, approved), Novartis (Chinook)'s Fabhalta (Iptacopan, factor B inhibitor, approved) and Vanrafia (Atrasentan, endothelin A receptor antagonist, approved) and Zigakibart (anti-APRIL monoclonal antibody, Phase 3), Otsuka (Visterra)'s Voyxact (Sibeprenlimab, monoclonal antibody, approved), Vera's Atacicept (recombinant fusion protein, Phase 3), Alexion (AstraZeneca)'s Ravulizumab (monoclonal antibody, Phase 3), Vertex (Alpine)'s Povetacicept (dual BAFF and APRIL inhibitor, Phase 3), RemeGen's Telitacicept (dual BAFF and APRIL inhibitor, Phase 3), Biogen (Hi-Bio)'s Felzartamab (monoclonal antibody, Phase 3), Takeda's Mezagitamab (monoclonal antibody, Phase 3), and Walden Biosciences' WAL0921 (uPAR antagonist, Phase 2).
• **Ulefnersen (FUS-ALS):** No other medicines in clinical development for FUS-ALS are mentioned, indicating a potential first-in-class opportunity.

Corporate Governance

Legal Proceedings

• On September 10, 2025, Arrowhead Pharmaceuticals, Inc. filed a lawsuit in the District of Delaware seeking a declaratory judgment that Ionis' patent US9,593,333 is invalid or not infringed by its ApoCIII inhibitor, plozasiran.
• On September 11, 2025, Ionis filed a lawsuit in the Central District of California asserting infringement of the same patent by Arrowhead's announced intention to commercialize plozasiran.
• On December 23, 2025, the Delaware Lawsuit was dismissed in favor of the California Lawsuit, consolidating the dispute in the Central District of California.
• On January 12, 2026, Arrowhead filed its Answer to Ionis' Complaint and Counterclaims in the Central District of California, continuing the legal dispute.

Stakeholder Impact

• **Shareholders:** Potential for increased value from new product launches and pipeline advancements, but also risks from ongoing net losses, intense competition, regulatory hurdles, and stock price volatility. Dilution risk from future common stock sales related to convertible notes and warrants.
• **Patients:** Development and commercialization of innovative, life-changing RNA-targeted medicines for serious diseases (e.g., FCS, HAE, ATTRv-PN, SMA, ALS, AxD, AS, CHB, Lp(a)-driven CVD, IgAN, FUS-ALS) offer new and improved treatment options.
• **Employees:** Commitment to fostering an inclusive culture, competitive compensation and benefits, and robust training and development programs. High importance placed on retaining experienced personnel for future success.
• **Partners:** Collaborative arrangements provide funding and development resources, but partners' strategic decisions and performance can significantly impact program progress and commercialization outcomes.
• **Regulatory Authorities:** Subject to extensive regulation by the FDA and foreign equivalents, requiring continuous compliance with cGMP, approval processes, and post-marketing requirements, influencing market access and product lifecycle.
• **Creditors:** Obligations related to convertible notes and mortgage debt, with ongoing financial management to ensure repayment and maintain creditworthiness.

Next Steps

• Launch olezarsen for severe hypertriglyceridemia (sHTG) following anticipated regulatory approval (PDUFA action date June 30, 2026).
• Launch zilganersen for Alexander disease in the second half of 2026, following NDA submission in January 2026.
• Continue to advance wholly-owned medicines in development, including obudanersen in Phase 3 for Angelman syndrome.
• Biogen's higher dose SPINRAZA is under review in the U.S. with a PDUFA action date of April 3, 2026.
• AstraZeneca is responsible for 75% and 87.5% of WAINUA development costs in the U.S. and rest of world, respectively, after December 31, 2025.
• Receive $200 million or $115 million payment upon regulatory approval of WAINUA for ATTR-CM in the U.S. or Europe, respectively.
• Receive $15 million payment if AstraZeneca advances a medicine under the cardiovascular, renal and metabolic collaboration.
• Receive $45 million payment if Biogen initiates a Phase 3 trial for salanersen.
• Receive up to $15 million if Biogen licenses a medicine under the 2018 neurology collaboration.
• Receive $25 million if Biogen advances IONIS-MAPTRx into Phase 3 development.
• Receive $15 million milestone payment if a New Drug Application filing for bepirovirsen is accepted for review in a major country.
• Receive $50 million payment if the FDA accepts an NDA filing for pelacarsen.
• Receive $20 million payment if Ono initiates a pivotal clinical trial for sapablursen.
• Receive $23.5 million payment if Roche advances sefaxersen for IgAN.
• Receive up to $17.5 million if Roche advances a medicine under the Huntingtons Disease collaboration.
• Receive $10 million payment if Roche initiates a Phase 2 trial for an investigational medicine for AD under the RNA-targeting AD/HD collaboration.
• Publish the 2025 Corporate Responsibility Report in April 2026.
• Initiate EU sites for the REVEAL study of obudanersen in 2026.
• Complete enrollment for the REVEAL study of obudanersen in 2026.
• Early adopt ASU 2025-06 in Q1 2026.

Key Dates

Recommendation

Ionis Pharmaceuticals demonstrated strong revenue growth in 2025, driven by successful new product launches and increased royalties from WAINUA. The robust late-stage pipeline with several upcoming regulatory decisions and launches in 2026 presents significant upside potential. However, the company continues to operate at a net loss, faces intense competition in key therapeutic areas, and is subject to substantial R&D and commercialization expenses. The stock has also experienced high volatility. A "hold" recommendation is appropriate as the company navigates its transition to a fully integrated commercial-stage entity, balancing promising pipeline advancements with the challenges of achieving consistent profitability and market penetration in competitive landscapes.

Keywords

RNA-targeted medicines, biotechnology, pharmaceuticals, drug development, commercialization, rare diseases, cardiometabolic diseases, neurology, clinical trials, SEC filing, 10-K, Ionis Pharmaceuticals, TRYNGOLZA, DAWNZERA, WAINUA, SPINRAZA, QALSODY, TEGSEDI, WAYLIVRA, olezarsen, zilganersen, obudanersen, bepirovirsen, eplontersen, pelacarsen, sefaxersen, ulefnersen, familial chylomicronemia syndrome, severe hypertriglyceridemia, hereditary angioedema, transthyretin-mediated amyloidosis, spinal muscular atrophy, amyotrophic lateral sclerosis, Angelman syndrome, chronic hepatitis B, hyperlipoproteinemia(a), immunoglobulin A nephropathy, FUS-ALS, gene editing, corporate partnerships, financial results, revenue, net loss, cash flow, regulatory approval, PDUFA, NDA, Phase 3, R&D